JP2025504543A - Ｂｔｌａに対する抗体及びその使用 - Google Patents

Ｂｔｌａに対する抗体及びその使用 Download PDF

Info

Publication number
JP2025504543A
JP2025504543A JP2024544441A JP2024544441A JP2025504543A JP 2025504543 A JP2025504543 A JP 2025504543A JP 2024544441 A JP2024544441 A JP 2024544441A JP 2024544441 A JP2024544441 A JP 2024544441A JP 2025504543 A JP2025504543 A JP 2025504543A
Authority
JP
Japan
Prior art keywords
seq
antigen
sequence
antibody
monoclonal antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024544441A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025504543A5 (https=
Inventor
ジュイン リー
チェン ジャン
ビンキン シェン
フランシスコ エイドリアン
リアン シュワイツァー
Original Assignee
ハイファイバイオ（ホンコン）リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ハイファイバイオ（ホンコン）リミテッド filed Critical ハイファイバイオ（ホンコン）リミテッド
Publication of JP2025504543A publication Critical patent/JP2025504543A/ja
Publication of JP2025504543A5 publication Critical patent/JP2025504543A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Transplantation (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2024544441A 2022-01-29 2023-01-29 Ｂｔｌａに対する抗体及びその使用 Pending JP2025504543A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2022/075109 2022-01-29
CN2022075109 2022-01-29
PCT/CN2023/073699 WO2023143564A1 (en) 2022-01-29 2023-01-29 Antibody against btla and uses thereof

Publications (2)

Publication Number Publication Date
JP2025504543A true JP2025504543A (ja) 2025-02-12
JP2025504543A5 JP2025504543A5 (https=) 2025-10-17

Family

ID=87470720

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024544441A Pending JP2025504543A (ja) 2022-01-29 2023-01-29 Ｂｔｌａに対する抗体及びその使用

Country Status (12)

Country Link
US (1) US20250388673A1 (https=)
EP (1) EP4469482A4 (https=)
JP (1) JP2025504543A (https=)
KR (1) KR20240139083A (https=)
CN (1) CN118871465A (https=)
AR (1) AR128377A1 (https=)
AU (1) AU2023212896A1 (https=)
CA (1) CA3250219A1 (https=)
IL (1) IL314579A (https=)
MX (1) MX2024009309A (https=)
TW (1) TW202340253A (https=)
WO (1) WO2023143564A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2097447A4 (en) * 2006-11-15 2010-12-29 Medarex Inc HUMAN MONOCLONAL ANTIBODIES AGAINST BTLA AND METHODS OF USE
BR112012007875A2 (pt) * 2009-07-31 2016-11-22 Medarex Inc anticorpos totalmente humanos para btla
MX2018010295A (es) * 2016-02-26 2019-06-06 Inst Nat Sante Rech Med Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
CN110790837A (zh) * 2018-08-02 2020-02-14 上海君实生物医药科技股份有限公司 抗btla抗体

Also Published As

Publication number Publication date
AU2023212896A1 (en) 2024-08-22
WO2023143564A1 (en) 2023-08-03
EP4469482A4 (en) 2026-05-06
AR128377A1 (es) 2024-04-24
TW202340253A (zh) 2023-10-16
US20250388673A1 (en) 2025-12-25
IL314579A (en) 2024-09-01
MX2024009309A (es) 2024-08-27
CA3250219A1 (en) 2023-08-03
EP4469482A1 (en) 2024-12-04
KR20240139083A (ko) 2024-09-20
CN118871465A (zh) 2024-10-29

Similar Documents

Publication Publication Date Title
TWI564305B (zh) 治療性抗體
RU2563344C2 (ru) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К Toll-ПОДОБНЫМ РЕЦЕПТОРАМ 2 И ИХ ПРИМЕНЕНИЯ
JP7179743B2 (ja) 抗ＳＩＲＰｇ抗体の新規の使用
CA2977621C (en) Antibody binding to tfpi and composition comprising the same
JP2018536401A (ja) 抗ｐｄ−ｌ１抗体、その抗原結合フラグメントおよびその医療用途
TW201132353A (en) WISE binding agents and epitopes
TW202229340A (zh) 多特異性抗體及抗體組合
CN114096275B (zh) 新型bssl抗体
EP4132582A1 (en) Targeted reduction of activated immune cells
JP7756686B2 (ja) ネコＭｃＤｏｎｏｕｇｈ肉腫（ＦＭＳ）様チロシンキナーゼ３受容体リガンド（ＦＬＴ３Ｌ）に対する抗体並びに自己免疫疾患及び炎症性疾患を治療するためのそれらの使用
US20250388673A1 (en) Antibody against btla and uses thereof
WO2023237928A2 (en) Igf1r antibodies
JP2025503707A (ja) ガレクチン－１０抗体
KR20240004332A (ko) 폰 빌레브란트 인자(vwf) 억제제
HK40114352A (zh) 针对btla的抗体及其用途
RU2826992C2 (ru) Новые антитела к bssl
JP7754841B2 (ja) ヒト化抗ヒトｃｄ８９抗体及びその使用
TW202342517A (zh) 使用抗組織因子抗體之炎性疾病治療
JP2026071208A (ja) Ｂｃｍａに結合する多重特異性抗体
TW202600594A (zh) 結合構築體(一)
CA3030320C (en) Humanized anti-s100a9 antibody and uses thereof
EA050239B1 (ru) Мультиспецифические антитела, связывающиеся с bcma
HK40062205A (en) Novel bssl antibodies
EA053218B1 (ru) Антитела на основе тяжелых цепей, связывающиеся с альфа-рецептором фолата
EA052946B1 (ru) Антитела, содержащие только тяжелые цепи, которые связываются с cd22

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251007

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251007